NCT06649695View on ClinicalTrials.gov

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
AL Amyloidosis
Interventions
DRUG

Teclistamab

Teclistamab will be administered via a subcutaneous injection (SC)

Trial Locations (10)

Unknown

NOT_YET_RECRUITING

South Australia Health, Adelaide

RECRUITING

Westmead Hospital, Sydney

NOT_YET_RECRUITING

CHU Limoges, Limoges

NOT_YET_RECRUITING

Paris St Louis, Paris

RECRUITING

University Hospital Essen, Essen

RECRUITING

University Hospital Heidelberg, Heidelberg

NOT_YET_RECRUITING

University Hospital Würzburg, Würzburg

RECRUITING

"General Hospital of Athens Alexandra", Athens

NOT_YET_RECRUITING

"Fondazione I.R.C.C.S Policlinico San Matteo", Pavia

RECRUITING

UMC Utrecht, Utrecht

Sponsors
All Listed Sponsors
collaborator

Janssen Research & Development

UNKNOWN

lead

European Myeloma Network B.V.

NETWORK